Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, <i>RAS</i> wild-type colorectal cancer: OGSG 1602.
Katsuya Ohta(Tokyo Medical and Dental University), Hisato Kawakami(Tohoku University), Kazuhiro Yanagihara(Kansai Electric Power (Japan)), Yoshinori Kagawa(Osaka International Cancer Institute), Ken Konishi(Hyogo Prefectural Nishinomiya Hospital), Tetsuji Terazawa(Osaka Medical and Pharmaceutical University), Yukinori Kurokawa(The University of Osaka), Hironaga Satake(Kobe City Medical Center General Hospital), Masahito Kotaka(Shimizu (Japan)), Taroh Satoh(Osaka University Hospital), Masayuki Hiraki(Osaka Health Science University), Toshio Shimokawa(Wakayama Medical University), Ken Nakata(Sakai Municipal Hospital), Takeshi Kato(Osaka National Hospital), Daisuke Sakai(Osaka International Cancer Institute), Masahiro Goto(Osaka Medical and Pharmaceutical University), Hiroko Hasegawa(Osaka National Hospital), Shiro Nakae(Sakai Municipal Hospital), Tatsushi Shingai(Kinki Central Hospital), Shingo Noura(Osaka Rosai Hospital)
Cited by 2
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411